Stryker Co. (NYSE:SYK) Shares Sold by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC lessened its stake in Stryker Co. (NYSE:SYK) by 0.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 33,608 shares of the medical technology company’s stock after selling 115 shares during the quarter. Stryker comprises about 0.8% of Knights of Columbus Asset Advisors LLC’s holdings, making the stock its 28th largest holding. Knights of Columbus Asset Advisors LLC’s holdings in Stryker were worth $12,101,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. J. W. Coons Advisors LLC boosted its holdings in Stryker by 0.7% in the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company’s stock valued at $1,315,000 after purchasing an additional 26 shares in the last quarter. Mascoma Wealth Management LLC boosted its holdings in Stryker by 22.7% in the 4th quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company’s stock valued at $53,000 after purchasing an additional 27 shares in the last quarter. Opal Wealth Advisors LLC boosted its holdings in Stryker by 1.6% in the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company’s stock valued at $654,000 after purchasing an additional 28 shares in the last quarter. Lindbrook Capital LLC boosted its holdings in Stryker by 2.0% in the 4th quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company’s stock valued at $507,000 after purchasing an additional 28 shares in the last quarter. Finally, Capital & Planning LLC boosted its holdings in Stryker by 3.6% in the 4th quarter. Capital & Planning LLC now owns 841 shares of the medical technology company’s stock valued at $304,000 after purchasing an additional 29 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Down 0.8 %

Shares of NYSE SYK opened at $371.38 on Friday. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a market cap of $141.71 billion, a P/E ratio of 47.86, a P/E/G ratio of 2.93 and a beta of 0.95. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The stock has a fifty day moving average price of $384.28 and a 200 day moving average price of $373.93.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the company posted $3.46 earnings per share. Research analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.90%. Stryker’s payout ratio is currently 43.30%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on SYK. Stifel Nicolaus boosted their price target on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. The Goldman Sachs Group set a $422.00 price target on Stryker in a research note on Tuesday, March 4th. Barclays boosted their price target on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, March 6th. Finally, Argus set a $450.00 target price on Stryker in a research note on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $421.90.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.